Shire PLC (LON:SHP)‘s stock had its “buy” rating reiterated by Deutsche Bank AG in a research report issued on Friday.
Several other analysts also recently commented on the stock. Barclays PLC started coverage on shares of Shire PLC in a research report on Wednesday, March 8th. They set an “overweight” rating and a GBX 6,500 ($81.14) price objective for the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a GBX 6,000 ($74.90) price objective on shares of Shire PLC in a research report on Monday, March 27th. BNP Paribas reaffirmed an “outperform” rating and set a GBX 5,900 ($73.65) price objective on shares of Shire PLC in a research report on Wednesday, December 21st. Citigroup Inc reaffirmed a “buy” rating on shares of Shire PLC in a research report on Tuesday, January 24th. Finally, Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($68.66) price objective on shares of Shire PLC in a research report on Thursday, March 9th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and a consensus target price of GBX 6,115.60 ($76.34).
Shares of Shire PLC (LON:SHP) opened at 4560.00 on Friday. The firm’s 50-day moving average is GBX 4,804.15 and its 200 day moving average is GBX 4,755.39. The company’s market capitalization is GBX 41.16 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.
The firm also recently declared a dividend, which will be paid on Tuesday, April 25th. Investors of record on Thursday, March 9th will be given a GBX 20.64 ($0.26) dividend. The ex-dividend date is Thursday, March 9th. This represents a yield of 0.43%. This is an increase from Shire PLC’s previous dividend of $3.51.
In other Shire PLC news, insider William Burns purchased 136 shares of Shire PLC stock in a transaction that occurred on Friday, March 31st. The stock was acquired at an average price of GBX 4,742 ($59.19) per share, with a total value of £6,449.12 ($8,050.33).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.